- Home
- AEI vs APRE Comparison
AEI vs APRE Comparison
Compare AEI & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEI
- APRE
- Stock Information
- Founded
- AEI 2014
- APRE 2006
- Country
- AEI United States
- APRE United States
- Employees
- AEI N/A
- APRE N/A
- Industry
- AEI Building operators
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AEI Real Estate
- APRE Health Care
- Exchange
- AEI Nasdaq
- APRE Nasdaq
- Market Cap
- AEI 10.9M
- APRE 10.0M
- IPO Year
- AEI N/A
- APRE 2019
- Fundamental
- Price
- AEI $1.06
- APRE $1.80
- Analyst Decision
- AEI
- APRE Strong Buy
- Analyst Count
- AEI 0
- APRE 2
- Target Price
- AEI N/A
- APRE $15.50
- AVG Volume (30 Days)
- AEI 115.7K
- APRE 50.9K
- Earning Date
- AEI 08-12-2025
- APRE 08-11-2025
- Dividend Yield
- AEI N/A
- APRE N/A
- EPS Growth
- AEI N/A
- APRE N/A
- EPS
- AEI N/A
- APRE N/A
- Revenue
- AEI $16,097,995.00
- APRE $1,284,475.00
- Revenue This Year
- AEI N/A
- APRE N/A
- Revenue Next Year
- AEI N/A
- APRE N/A
- P/E Ratio
- AEI N/A
- APRE N/A
- Revenue Growth
- AEI N/A
- APRE 33.27
- 52 Week Low
- AEI $0.70
- APRE $1.41
- 52 Week High
- AEI $2.61
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- AEI 56.70
- APRE 49.58
- Support Level
- AEI $0.98
- APRE $1.64
- Resistance Level
- AEI $1.30
- APRE $1.81
- Average True Range (ATR)
- AEI 0.11
- APRE 0.15
- MACD
- AEI 0.02
- APRE -0.01
- Stochastic Oscillator
- AEI 52.43
- APRE 51.76
About AEI Alset Inc. (TX)
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.